|
|
2008-10-02  BUSINESS | Nasdaq to delist Alpharetta's AtheroGenics
|
|  |
October 10, 2008
AtheroGenics Inc. (NASDAQ: AGIX) today reported that it received notification from the Nasdaq Stock Market indicating that the staff of the Nasdaq Stock Market had determined that the company's common stock should be delisted from the Nasdaq Global Market in light of its filing under Chapter 11 of the U.S. Bankruptcy Code.
Trading in the Company's common stock on the Nasdaq Global Market will be suspended at the opening of business on Oct. 14. AtheroGenics expects that its common stock will continue to trade on the over-the-counter market or the Pink Sheets.
AtheroGenics is focused on the discovery, development and commercialization of potential drug candidates for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being developed for the treatment of Type 2 diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, visit http://www.atherogenics.com.
- www.northfulton.com
| |
| |
|
|
| |
|
